EU clears Eylea 8 mg for retinal vein occlusion, expanding use of long-acting eye therapy
Treatment typically requires frequent injections directly into the eye—an ongoing burden for patients and health systems alike
Treatment typically requires frequent injections directly into the eye—an ongoing burden for patients and health systems alike
The researchers removed a chemical group commonly used in previous NK1R drugs and replaced it with a novel molecular scaffold
Projects selected for advancement will move forward through the Harvard Office of Technology Development’s processes for sponsored research agreements
Preclinical studies show that 4P004 modulates multiple biological markers across the joint, potentially slowing structural damage while improving function
After leading AstraZeneca's Oncology areas nationally and internationally, Laura Colón will assume the presidency of AstraZeneca in one of its priority global markets
The new assets expand Biocon Biologics’ already robust oncology portfolio, which now includes 17 cancer therapies
Blood tests measuring biomarkers such as p-tau217 are emerging as accurate, accessible alternatives
Subscribe To Our Newsletter & Stay Updated